In a patient with suspected hepatic steatosis, mild chronic liver disease, prior FibroScan indicating fibrosis, and a small enhancing focus in segment 5 of the right hepatic lobe, should a liver MRI with elastography be performed when serum ferritin is >1350 µg/L?

Yes, proceed with MRI with elastography (MRE) for this patient with ferritin >1350 µg/L

Given the ferritin level exceeding 1350 µg/L (well above the 1,000 µg/L threshold), combined with existing evidence of hepatic fibrosis on prior FibroScan, chronic liver disease features, and a small indeterminate hepatic lesion, MRI with elastography is strongly indicated to comprehensively assess both iron overload and fibrosis severity, which are critical determinants of morbidity and mortality.

Rationale Based on Guidelines

The 2022 EASL Clinical Practice Guidelines on Haemochromatosis provide clear direction for this clinical scenario 1:

Ferritin >1,000 µg/L Triggers Advanced Assessment

• When serum ferritin exceeds 1,000 µg/L, non-invasive assessment of both fibrosis and iron burden becomes essential 1
• At ferritin <1,000 µg/L without hepatomegaly, thrombocytopenia, or elevated transaminases, the negative predictive value for advanced fibrosis is 94% 1
• Your patient's ferritin of >1,350 µg/L places them in the high-risk category where advanced fibrosis cannot be excluded without further evaluation

MRI Provides Dual Assessment

The guidelines specifically recommend MRI in patients with elevated ferritin and additional risk factors 1:

• MRI R2 sequences reliably quantify hepatic iron concentration* and predict organ damage 1
• In patients with chronic liver disease (which your patient has) and elevated ferritin, non-invasive quantification of liver iron guides both diagnosis and management 1
• MRI elastography (MRE) simultaneously assesses liver stiffness as a marker of fibrosis 1

Your Patient's Specific Indications

This patient has multiple converging indications:

1. Ferritin >1,350 µg/L - exceeds the 1,000 µg/L threshold requiring fibrosis assessment 1
2. Prior FibroScan showing fibrosis - needs confirmation and staging
3. Chronic liver disease features (fissural changes, suspected steatosis)
4. Indeterminate 1-2 mm enhancing focus in segment 5 requiring characterization
5. Possible iron overload (elevated ferritin) requiring quantification

Why MRI with Elastography Over Other Options

Superior to Liver Biopsy

• Liver biopsy is no longer recommended for diagnosing hepatic iron overload 1
• Non-invasive methods have largely replaced biopsy for assessing both iron burden and fibrosis severity 1
• Biopsy would only be considered if cirrhosis cannot be confirmed or excluded by non-invasive means 1

MRE Outperforms Standard Elastography

Recent evidence demonstrates MRE's superiority 2:

• MRE identified fibrosis stage ≥2 with AUROC 0.91 vs. transient elastography's 0.82 (p=0.001) 2
• MRE has the highest diagnostic performance among all non-invasive tests for staging liver fibrosis 3

Comprehensive Single-Study Assessment

MRI with elastography provides:

• Iron quantification via R2 sequences* 1
• Liver stiffness measurement (fibrosis staging) 1
• Steatosis quantification via PDFF 2, 4
• Characterization of the segment 5 lesion (differentiating hemangioma from other etiologies)
• Assessment for HCC risk in the setting of fibrosis 5

Clinical Algorithm for This Patient

Step 1: Order MRI liver with:

• MR elastography (liver stiffness measurement)
• R2* iron quantification sequences
• PDFF for steatosis quantification
• Dynamic contrast-enhanced sequences for lesion characterization

Step 2: Simultaneously obtain:

• Complete iron panel (transferrin saturation, serum iron, TIBC)
• HFE gene testing (C282Y and H63D mutations)
• Liver enzymes (AST, ALT)
• Complete blood count with platelets
• FIB-4 score calculation

Step 3: Based on MRI results:

• If hepatic iron concentration elevated + MRE shows significant fibrosis (>8 kPa): Initiate phlebotomy therapy and HCC surveillance
• If iron overload confirmed without significant fibrosis: Phlebotomy with less intensive monitoring
• If lesion characteristics concerning: Proceed to biopsy or enhanced surveillance

Key Pitfalls to Avoid

Don't Rely on Ferritin Alone

Ferritin is non-specific and elevated in inflammatory and neoplastic conditions 1. The combination of ferritin >1,000 µg/L with chronic liver disease mandates tissue assessment, but this should be non-invasive 1.

Don't Assume Steatosis Explains Everything

While steatosis is suspected, hyperferritinemia is itself a risk factor for steatosis 6, and iron overload may be an independent contributor to liver injury requiring specific treatment.

Don't Delay Assessment

Severe liver fibrosis correlates with iron overload severity and increases HCC risk 1. Early identification allows for therapeutic intervention (phlebotomy) that can prevent progression.

Don't Order Incomplete MRI Protocol

Ensure the MRI includes all three components: elastography, R2* iron quantification, and PDFF. A standard contrast MRI without these quantitative sequences will miss critical diagnostic information 1.

Prognostic Implications

The guidelines emphasize that all patients with suspected iron overload and chronic liver disease should be non-invasively assessed for fibrosis at diagnosis to guide treatment and follow-up 1. This is a strong recommendation with strong consensus 1.

MRI findings will directly impact:

• Need for phlebotomy therapy
• Intensity of HCC surveillance (if advanced fibrosis/cirrhosis confirmed)
• Prognosis (fibrosis stage is the principal determinant of liver-related outcomes) 7
• Treatment monitoring strategy

The small enhancing lesion also requires definitive characterization, as patients with fibrosis and metabolic liver disease have altered HCC risk even without cirrhosis 8.